[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intraperitoneal-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intraperitoneal-chemotherapy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100617191","chewing-gum-flavors-to-reduce-postoperative-nausea-and-vomiting-after-pipac-100617191",false,"NCT07315412","Chewing Gum Flavors to Reduce Postoperative Nausea and Vomiting After PIPAC","Comparative Effectiveness of Ginger-Mint and Cinnamon-Flavored Gum in Preventing Nausea and Vomiting Following Pressurized Intraperitoneal Aerosol Chemotherapy","Inclusion Criteria:\n\n* Adults aged 18 years or older undergoing Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).\n* Able to communicate, understand study instructions, and provide written informed consent.\n* No known allergy or intolerance to ginger, mint, or cinnamon.\n* Able and willing to chew gum for 15 minutes.\n* Apfel risk score ≥3 for postoperative nausea and vomiting.\n\nExclusion Criteria:\n\n* Postoperative complications requiring intensive care or reoperation.\n* Need for rescue antiemetic medication within the first 2 postoperative hours.\n* History of psychiatric disorder, neurological disease, or cognitive impairment affecting participation.\n* Anatomical or functional limitation preventing chewing (e.g., full dentures, jaw restriction, oral surgery).\n* Known phenylketonuria or metabolic intolerance to chewing gum ingredients.\n* Active chemotherapy, radiotherapy, or immunosuppressive therapy affecting gastrointestinal function.","ALL","18 Years","80 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled clinical trial aims to evaluate the effectiveness of chewing gum with different natural flavors in reducing postoperative nausea and vomiting (PONV) following Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Adult patients undergoing PIPAC will be randomly assigned to one of three groups: (1) ginger-mint flavored gum, (2) cinnamon flavored gum, or (3) control group with standard postoperative care only. Participants in the intervention arms will chew one piece of gum for 15 minutes in the post-anesthesia care unit (PACU). Nausea intensity (Numeric Rating Scale, 0-10) and the presence of vomiting or retching will be assessed at baseline and every 15 minutes for 2 hours.\n\nThe study hypothesizes that ginger-mint and cinnamon flavored chewing gums, both plant-based and certified vegan, will be effective, non-pharmacological, and safe methods to reduce nausea and vomiting after PIPAC. This research may contribute to enhanced postoperative comfort and faster recovery by supporting the principles of Enhanced Recovery After Surgery (ERAS).",[27,28,29],"Postoperative Nausea and Vomiting (PONV)","Peritoneal Metastases From Colorectal Cancer","Intraperitoneal Chemotherapy",[31,32,33,34,35,36,37],"Chewing gum","ginger","cinnamon","postoperative neusea","vomiting","eras","supportive care","NOT_YET_RECRUITING","2025-12-23",{"date":41,"type":42},"2026-01-02","ACTUAL",{"date":44,"type":21},"2025-12-10",{"date":46,"type":21},"2027-05-30",{"name":48,"class":49},"Fenerbahce University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100384182","phase-2-intensive-intraperitoneal-therapy-in-advanced-ovarian-cancer-100384182","NCT04282356","Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer","Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer Combining Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Postoperative Intraperitoneal Chemotherapy (IPC)","INTENS-IP","Inclusion Criteria:\n\n* Patients aged 18 to 75 years,\n* Patients with high-grade serous (high grade according to MD Anderson, grade II and III according to Silverman) ovarian or tubal or primitive peritoneal histologically proven cancer,\n* Initial laparoscopy confirming the histological type, evaluating the extent of the disease by PCI score and confirming the initial non-resectability,\n* Stage III B-C (FIGO 2014) or stage IVA with minimal or moderate pleural effusion (measured on a thoracic CT scanner, the largest thickness of which is less than 3 cm),\n* Complete interval cytoreduction surgery,\n* Indication of 3 to 4 cures of neoadjuvant chemotherapy based on the Carboplatin-Paclitaxel (carbo-taxol) combination,\n* The delay between the last course of NAT and the surgery must be between 4 and 8 weeks,\n* Hematologic function, hemoglobin ≥ 10 g \u002F dl; PNN ≥ 1 x 109 \u002F L, platelets ≥ 100 x 109 \u002F L,\n* Total bilirubin ≤ 1.5 LSN, ALT or AST ≤ 3 ULN,\n* Absence of renal insufficiency (creatinine clearance ≤ 70 ml \u002F min) according to the MDRD method,\n* Informed consent signed before any specific procedure under consideration,\n* Patients affiliated to the French social security scheme or equivalent.\n\nExclusion Criteria:\n\n* Performance Index (WHO) ≥ 2,\n* Stage IV B or IV A with significant pleural effusion (measured on a thoracic CT scanner, the largest thickness of which is more than 3 cm),\n* Renal impairment (clearance \\\u003C70 ml \u002F min) according to the MDRD method,\n* General contraindication to the realization of a tumor reduction surgery or HIPEC (contraindication or history allergic reaction to any treatments components),\n* Hepatic insufficiency (bilirubin \\> 1.5 x normal, ASAT \\& ALAT \\> 3 x upper limit of normal),\n* Serious life-threatening co-existing condition at stake,\n* Cardio-respiratory pathology indicating hyper hydration, to be implemented for HIPEC,\n* Patient who has already been treated with chemo-hyperthermia for ovarian cancer,\n* History of cancer, except basal cell carcinoma of the skin or carcinoma in situ of cervix having recurred within five years prior to entry into this trial,\n* Any severe untreated infectious disease,\n* Peripheral sensory neuropathy ≥ grade 2 at the inclusion time,\n* Patients whose regular follow-up is a priori impossible for psychological, family, social or geographical reasons,\n* Pregnant and \u002F or nursing women,\n* Subjects under tutelage, curatorship or safeguard of justice.","FEMALE","75 Years",{"count":62,"type":21},55,[64],"PHASE2","Clinicians postulate that it may be interesting to combine the two IntraPeritoneal (IP) treatments associated with a significant improvement of OC overall survival i.e. cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and postoperative intraperitoneal chemotherapy (IPC) as an \" intensive peritoneal \" regimen in the initial management of stages III-IVA ovarian cancers. Performing a postoperative IPC may allow completing and extending the duration of the effect of HIPEC in decreasing the risk of peritoneal recurrence. HIPEC may also allow administering an early IP treatment on the residual microscopic disease during initial or interval surgery with an optimal access to the intraperitoneal cavity. Postoperative IPC will extend the HIPEC effect on unsterilized peritoneal microscopic residues with the aim of decreasing the risk of local recurrence. Performing HIPEC before IPC could allow limiting the number of postoperative IP courses needed. Nevertheless, this association questions its feasibility and tolerance, which should both be assessed in a phase II trial. Clinicians propose to conduct this feasibility study combining for the first time HIPEC with IPC as first-line treatment of ovarian cancer with peritoneal carcinomatosis to perform a peritoneal intensification.",[67,29],"Ovarian Cancer",[69,70,71,72,73],"ovarian cancer","intraperitoneal","chemotherapy","surgery","HIPEC","RECRUITING","2025-02-11",{"date":77,"type":42},"2025-02-12",{"date":79,"type":42},"2020-09-15",{"date":81,"type":21},"2030-12",{"name":83,"class":49},"Institut du Cancer de Montpellier - Val d'Aurelle"]